# Brain Irradiation and Tremelimumab in Metastatic Breast Cancer

> **NCT02563925** · NA · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 28 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **RADIATION:** Brain radiotherapy or Stereotactic Radiosurgery
- **DRUG:** Tremelimumab
- **DRUG:** HER2 directed therapy
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT02563925
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-18
- **Primary completion:** 2021-07-14
- **Final completion:** 2021-07-14
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02563925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02563925, "Brain Irradiation and Tremelimumab in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02563925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*